



Supplementary Fig. S1. Inefficacy event-free cumulative retention of secukinumab compared to TNF- α inhibitors in biologic experienced patients.

Supplementary Table S1. Inefficacy events according to body mass index group and drug.

Drug	BMI category	Inefficacy events (n/total)	HR (95%CI)	p-value
All	18.5-24.9	37.1% (59/159)	1	0.004
	25-34.9	42.4% (169/399)	1.22 (0.91-1.64)	0.195
	≥ 35	54.7% (47/86)	1.89 (1.29-2.77)	0.001
SEC	18.5-24.9	23.5% (4/17)	1	0.485
	25-34.9	35.1% (20/57)	1.54 (0.53-4.5)	0.432
	≥ 35	37.5% (6/16)	2.18 (0.64-7.74)	0.230
ETA	18.5-24.9	32.7% (16/49)	1	0.007
	25-34.9	42.1% (45/107)	1.53 (0.77-2.4)	0.298
	≥ 35	66.75% (14/21)	3.02 (1.47-6.22)	0.003
IFX	18.5-24.9	28.6% (4/14)	1	0.317
	25-34.9	36.8% (21/57)	1.47 (0.5-4.29)	0.480
	≥ 35	58.3% (7/12)	2.47 (0.72-8.5)	0.152
ADA	18.5-24.9	43.4% (23/53)	1	0.121
	25-34.9	44% (55/125)	1.06 (0.65-1.72)	0.828
	≥ 35	60% (15/25)	1.85 (0.97-3.55)	0.064
GOL	18.5-24.9	46.2% (12/26)	1	0.633
	25-34.9	52.8% (28/53)	1.32 (0.67-2.6)	0.421
	≥ 35	41.7% (5/12)	0.95 (0.33-2.71)	0.925

BMI: Body Mass index; HR: hazard ratio; CI: confidence interval; SEC: secukinumab; ETA: etanercept; IFX: infliximab; ADA: adalimumab; GOL: golimumab.